Screening of Living Kidney Donors for Genetic Diseases: CON.
作者信息
Thomas Christie P
机构信息
Department of Internal Medicine and Iowa Institute of Human Genetics, University of Iowa Carver College of Medicine, Iowa City, Iowa and VA Medical Center, Iowa City, Iowa.
出版信息
Kidney360. 2024 Oct 1;5(10):1413-1415. doi: 10.34067/KID.0000000000000353. Epub 2024 May 15.
Abstract
摘要
相似文献
1
Screening of Living Kidney Donors for Genetic Diseases: CON.活体肾供体遗传性疾病筛查：反对意见
Kidney360. 2024 Oct 1;5(10):1413-1415. doi: 10.34067/KID.0000000000000353. Epub 2024 May 15.
2
Prevalence of High-Grade Anal Dysplasia and Anal Cancer in Veterans Living With HIV and CD4/CD8 Ratio as a Marker For Increased Risk: A Regional Retrospective Cohort Study.在伴有 HIV 的退伍军人中，高级别肛门发育异常和肛门癌的流行率以及 CD4/CD8 比值作为高风险标志物：一项区域性回顾性队列研究。
Dis Colon Rectum. 2021 Jul 1;64(7):805-811. doi: 10.1097/DCR.0000000000002009.
3
Screening and follow-up of living kidney donors: a systematic review of clinical practice guidelines.活体肾捐献者的筛查和随访：临床实践指南的系统评价。
Transplantation. 2011 Nov 15;92(9):962-72. doi: 10.1097/TP.0b013e3182328276.
4
Utility of Genetic Information for Management in Kidney Transplantation and Living Donation.基因信息在肾移植和活体供肾管理中的应用价值。
Semin Nephrol. 2025 Jul;45(4):151658. doi: 10.1016/j.semnephrol.2025.151658. Epub 2025 Jul 17.
5
Cardiovascular and kidney outcomes of living kidney donors with preexisting hypertension: A systematic review and meta-analysis.患有高血压的活体肾供者的心血管和肾脏结局：一项系统评价和荟萃分析。
Am J Hypertens. 2025 Jun 26. doi: 10.1093/ajh/hpaf114.
6
Metabolic risk after living kidney donation: an analysis of the Swiss Organ Living-Donor Health Registry.活体肾捐献后的代谢风险：瑞士器官活体捐献者健康登记处的分析
Swiss Med Wkly. 2025 Jun 27;155:4513. doi: 10.57187/s.4513.
7
Anal Cancers in Previously Screened Versus Unscreened Patients: Tumor Stage and Treatment Outcomes.曾接受筛查与未接受筛查患者的肛管癌：肿瘤分期及治疗结果
Dis Colon Rectum. 2024 Jan 1;67(1):32-41. doi: 10.1097/DCR.0000000000002922. Epub 2023 Sep 26.
8
The Course and Predictors of Health-Related Quality of Life in Living Kidney Donors: A Systematic Review and Meta-Analysis.活体肾供体健康相关生活质量的病程及预测因素：一项系统评价与荟萃分析
Am J Transplant. 2015 Dec;15(12):3041-54. doi: 10.1111/ajt.13453. Epub 2015 Sep 28.
9
Genetic testing in the evaluation of recipient candidates and living kidney donors.遗传检测在受者候选人和活体供肾者评估中的应用。
Curr Opin Nephrol Hypertens. 2024 Jan 1;33(1):4-12. doi: 10.1097/MNH.0000000000000934. Epub 2023 Oct 12.
10
The direct and indirect economic costs incurred by living kidney donors-a systematic review.活体肾供者产生的直接和间接经济成本——一项系统综述
Nephrol Dial Transplant. 2006 Jul;21(7):1952-60. doi: 10.1093/ndt/gfl069. Epub 2006 Mar 22.
引用本文的文献
1
Screening of Living Kidney Donors for Genetic Diseases: Commentary.活体肾供体的遗传病筛查：评论
Kidney360. 2024 Oct 1;5(10):1419-1421. doi: 10.34067/KID.0000000000000470. Epub 2024 May 15.
本文引用的文献
1
Rates and Classification of Variants of Uncertain Significance in Hereditary Disease Genetic Testing.遗传性疾病基因检测中不确定意义变异的发生率和分类。
JAMA Netw Open. 2023 Oct 2;6(10):e2339571. doi: 10.1001/jamanetworkopen.2023.39571.
2
The landscape of reported VUS in multi-gene panel and genomic testing: Time for a change.多基因panel 及基因组检测中报告的 VUS 景观：是时候改变了。
Genet Med. 2023 Dec;25(12):100947. doi: 10.1016/j.gim.2023.100947. Epub 2023 Jul 30.
3
Genetic evaluation of living kidney donor candidates: A review and recommendations for best practices.活体肾捐献者候选人的遗传学评估：综述及最佳实践建议。
Am J Transplant. 2023 May;23(5):597-607. doi: 10.1016/j.ajt.2023.02.020. Epub 2023 Mar 1.
4
Exome Sequencing of a Clinical Population for Autosomal Dominant Polycystic Kidney Disease.常染色体显性遗传多囊肾病临床人群外显子组测序。
JAMA. 2022 Dec 27;328(24):2412-2421. doi: 10.1001/jama.2022.22847.
5
Prevalence Estimates of Predicted Pathogenic Variants in a Population Sequencing Database and Their Implications for Alport Syndrome.人群测序数据库中预测致病性变异的流行率估计及其对 Alport 综合征的影响。
J Am Soc Nephrol. 2021 Sep;32(9):2273-2290. doi: 10.1681/ASN.2020071065. Epub 2021 Jun 18.
6
Design and Reporting Considerations for Genetic Screening Tests.遗传筛查测试的设计和报告考虑因素。
J Mol Diagn. 2020 May;22(5):599-609. doi: 10.1016/j.jmoldx.2020.01.014. Epub 2020 Feb 22.
7
Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.Sherloc：ACMG-AMP 变异分类标准的全面细化。
Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11.
8
Quantifying Postdonation Risk of ESRD in Living Kidney Donors.量化活体肾供者捐献后发生终末期肾病的风险。
J Am Soc Nephrol. 2017 Sep;28(9):2749-2755. doi: 10.1681/ASN.2016101084. Epub 2017 Apr 27.
9
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.序列变异解读的标准与指南：美国医学遗传学与基因组学学会和分子病理学协会的联合共识推荐
Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.
10
Genetic tests: clinical validity and clinical utility.基因检测：临床有效性与临床实用性。
Curr Protoc Hum Genet. 2014 Apr 24;81:9.15.1-9.15.8. doi: 10.1002/0471142905.hg0915s81.
Zotero 插件